Patient Derived Tumor Xenografts: transforming clinical samples into mouse models
Cet article passe en revue les perspectives offertes par le recours à des xénogreffes, sur des souris immunodéficientes, de tumeurs de patients pour le développement de nouveaux traitements
Despite new insight into the pathogenesis and development of cancer, most novel therapies fail upon reaching Phase III clinical trials. This occurs even though millions of dollars are spent on target validation and drug optimization in preclinical models. When evaluating our approach to target discovery, we should consider if our current, powerful genomic technologies are being used on model systems that have poor clinical predictive power."Tumor graft models" (also known as Patient-Derived Xenografts or PDXs) are based on the transfer of primary tumors directly from the patient into an immunodeficient mouse. This review examines the development, challenges and broad utility of these attractive cancer models.
Cancer Research , résumé, 2013